portal.sina.com.hk ·
Coloplast a S Announcement No 05 2026 Interim Financial Report H1 2025 26
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedColoplast's earnings report shows steady organic growth across core segments, but a significant impairment on Kerecis goodwill indicates a write-down in the wound care acquisition's value. The negative currency effect (4%) impacts reported revenue. No direct commodity or supply chain scarcity is triggered; the commercial mechanism is company-specific margin and asset valuation. (not specified) for winners/losers.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Coloplast H1 2025/26 organic growth 6%, EBIT growth 5% in constant currencies.
- Reported revenue up 2% with 4% negative currency impact.
- Impairment loss of DKK 3.0 billion on Kerecis goodwill, reducing carrying value to ~DKK 6 billion.
- Half-year interim dividend of DKK 5.00 per share, total DKK 1,127 million.
- Segment growth: Ostomy Care 5%, Continence Care 7%, Interventional Urology 8%, Wound & Tissue Repair 1%.
Kerecis goodwill impairment indicates overvaluation in wound care, but core segments remain stable.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- GLOBAL_HEALTHCAREmid